brivanib alaninate
Small moleculeexperimental
Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC, the most common type of liver cancer. Brivanib is no longer in active development. — Wikipedia
Clinical trial activity
35 trials · 18 clinical orgs · 0 marketing orgs
Phase 1
17
Phase 2
19
Phase 3
6
Phase 4
0
Earliest trial started May 1, 2000 (NCT00437437)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Cholangitis · Phase 2
- Cholangitis, Sclerosing · Phase 2
- Colorectal Neoplasms · Phase 3
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Gastrointestinal Neoplasms · Phase 1
- Intestinal Neoplasms · Phase 1
- Liver Cirrhosis, Biliary · Phase 1
- Liver Neoplasms · Phase 3
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Non-alcoholic Fatty Liver Disease · Phase 2
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 2
- Sarcoma · Phase 2
- Stents · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Uterine Neoplasms · Phase 2
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Active metabolite of Brivanib alaninate
- Fibroblast growth factor receptorINHIBITOR
Fibroblast growth factor receptor inhibitor
Active metabolite of Brivanib alaninate
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1- Mol. weight
- 441.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- WikipediaBrivanib alaninate ↗
- ChEMBLCHEMBL377300 ↗
- ChEMBLCHEMBL270995 ↗
Also known as
- bms540215
- bms 540215
- bms-540215
- bms-540215
- bms-540215
- bms582664
- bms 582664
- bms-582664
- bms-582664
- bms-582664
- bms-582664
- brivanib
- brivanib
- brivanib
- brivanib
- brivanib
- brivanib alaninate
- brivanib alaninate
- brivanib alaninate
- brivanib alaninate
- brivanib alaninate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07282353 | Phase 3 | Dec 1, 2025 | Jiao Tong University |
| NCT06888115 | Phase 1 | Mar 13, 2025 | Soochow University |
| NCT06492330 | N/A | Jul 19, 2024 | Jiao Tong University |
| NCT06098027 | Phase 1 | Oct 23, 2023 | — |
| NCT05896124 | Phase 2 | Aug 7, 2023 | — |
| NCT05896137 | Phase 2 | Aug 7, 2023 | — |
| NCT05591079 | Phase 2 | Feb 28, 2023 | LabCorp |
| NCT05624294 | Phase 1 | Dec 9, 2022 | Jiao Tong University |
| NCT05082779 | Phase 1 | Oct 26, 2021 | Cascade Pharmaceuticals, Inc, Covance, LabCorp |
| NCT04395612 | Phase 2 | May 8, 2020 | Chongqing Medical University |
| NCT04212221 | Phase 1/Phase 2 (Phase 2) | Feb 29, 2020 | People's Liberation Army of China, Zai Lab Pty. Ltd. |
| NCT03895788 | Phase 1 | Jan 14, 2019 | Central South University |
| NCT03516071 | Phase 2 | May 10, 2017 | Zai Lab Pty. Ltd. |
| NCT01540461 | Phase 1 | Mar 1, 2012 | Bristol-Myers Squibb |
| NCT01367275 | Phase 2 | Aug 1, 2011 | Bristol-Myers Squibb, University of Texas at Houston |
| NCT01267253 | Phase 2 | Apr 1, 2011 | Gynecologic Oncology Group, National Cancer Institute (NCI), NRG Oncology |
| NCT01253668 | Phase 2 | Nov 1, 2010 | University of Pennsylvania |
| NCT01108705 | Phase 3 | May 1, 2010 | Bristol-Myers Squibb |
| NCT01046864 | Phase 1 | Feb 1, 2010 | Bristol-Myers Squibb |
| NCT00908752 | Phase 3 | Jul 20, 2009 | Bristol-Myers Squibb |
Showing 20 of 35 trials
Page 1 / 2
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 18 | 17 | 3 | 2000 |
| Jiao Tong University | Academic/Hospital | 3 | 1 | 3 | 2022 |
| Gynecologic Oncology Group | Academic/Hospital | 2 | 2 | 1 | 2009 |
| LabCorp | For profit | 2 | 0 | 2 | 2021 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2009 |
| NRG Oncology | Academic/Hospital | 2 | 0 | 1 | 2009 |
| Zai Lab Pty. Ltd. | For profit | 2 | 2 | 1 | 2017 |
| Bristol-Myers | For profit | 1 | 0 | 1 | 2007 |
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Cascade Pharmaceuticals, Inc | For profit | 1 | 1 | 1 | 2021 |
| Central South University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Chongqing Medical University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Covance | For profit | 1 | 0 | 1 | 2021 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2020 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2008 |
18 organizations
Page 1 / 1